Frank Rimerman Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.8M Hold
11,066
– – 0.71% 20
2026
Q2
$13.3M Buy
11,066
+732
+7% +$748K 0.75% 20
2026
Q1
$9.5M Sell
10,334
-458
-4% -$464K 0.62% 23
2025
Q4
$11.6M Buy
10,792
+2,295
+27% +$2.19M 0.74% 17
2025
Q3
$6.48M Buy
8,497
+390
+5% +$290K 0.42% 35
2025
Q2
$6.32M Sell
8,107
-800
-9% -$622K 0.42% 34
2025
Q1
$7.36M Buy
8,907
+202
+2% +$168K 0.58% 23
2024
Q4
$6.72M Sell
8,705
-5,744
-40% -$4.76M 0.49% 27
2024
Q3
$12.8M Buy
14,449
+695
+5% +$625K 0.91% 17
2024
Q2
$12.5M Buy
13,754
+13,690
+21,391% +$11M 0.88% 17
2024
Q1
$49.8K Hold
64
– – 0.01% 126
2023
Q4
$37.3K Buy
+64
New +$37.4K 0.01% 128

Other funds holding LLY

Frank Rimerman Advisors's LLY Position: Q3 2026 in Review

Frank Rimerman Advisors held its Eli Lilly (LLY) position steady in Q3 2026 at 11,066 shares worth $12.8M. The position accounts for 0.71% of the portfolio, ranked #20.

Frank Rimerman Advisors first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. The position peaked at $13.3M in Q2 2026. 1,509 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Frank Rimerman Advisors held 11,066 shares of Eli Lilly worth $12.8M as of Q3 2026.
  • Frank Rimerman Advisors left its Eli Lilly share count unchanged in Q3 2026.
  • Eli Lilly made up 0.71% of Frank Rimerman Advisors's portfolio in Q3 2026, its #20 holding.
  • Frank Rimerman Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
  • Frank Rimerman Advisors's Eli Lilly position peaked at $13.3M in Q2 2026.
  • 1,509 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Frank Rimerman Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.